You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 14, 2025

CLINICAL TRIALS PROFILE FOR ASTELIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Astelin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00660517 ↗ A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies Completed Meda Pharmaceuticals Phase 3 2007-12-01 The purpose of this study is to determine if two allergy medications (azelastine and fluticasone) are more effective than placebo or either medication alone (azelastine or fluticasone)
NCT00783432 ↗ Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis Completed Meda Pharmaceuticals Phase 3 2006-07-01 The purpose of this study is to determine if Astepro Nasal Spray (0.1% azelastine hydrochloride) is as safe as Astelin Nasal Spray (0.1% azelastine hydrochloride)
NCT00883168 ↗ A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies Completed Meda Pharmaceuticals Phase 3 2009-04-01 The purpose of this study is to determine if the combination of two allergy medications (formulated azelastine/fluticasone product)is more effective than placebo or either component medication alone (azelastine or fluticasone).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Astelin

Condition Name

Condition Name for Astelin
Intervention Trials
Seasonal Allergic Rhinitis 3
Allergic Rhinitis 1
Chronic Allergic Rhinitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Astelin
Intervention Trials
Rhinitis 6
Rhinitis, Allergic 5
Rhinitis, Allergic, Seasonal 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Astelin

Trials by Country

Trials by Country for Astelin
Location Trials
United States 25
Germany 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Astelin
Location Trials
Texas 3
New Jersey 2
Washington 1
Utah 1
Tennessee 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Astelin

Clinical Trial Phase

Clinical Trial Phase for Astelin
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Astelin
Clinical Trial Phase Trials
Completed 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Astelin

Sponsor Name

Sponsor Name for Astelin
Sponsor Trials
Meda Pharmaceuticals 3
Ligand Pharmaceuticals 1
Alcon Research 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Astelin
Sponsor Trials
Industry 7
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Azelastine (Astelin): Clinical Trials, Market Analysis, and Projections

Last updated: January 7, 2025

Introduction to Azelastine (Astelin)

Azelastine, marketed under the brand name Astelin among others, is an antihistamine used primarily to treat allergic rhinitis, including both seasonal (SAR) and perennial (PAR) forms. Here, we will delve into the clinical trials, market analysis, and future projections for azelastine.

Clinical Trials Overview

Seasonal Allergic Rhinitis (SAR) Trials

The clinical program for azelastine included several pivotal trials to establish its efficacy and safety in treating SAR. Key trials include:

  • Studies MP433 and MP438: These trials compared azelastine 0.15% nasal spray with active comparators (Astelin and Astepro, respectively) and placebo. Both trials demonstrated that azelastine had a numerically greater treatment effect over the active comparators, supporting its approval for twice-daily dosing[1].
  • Studies MP439 and MP440: These trials were designed to evaluate the efficacy of a once-daily dosing regimen. While MP439 failed to demonstrate significant efficacy at the dose trough, MP440 showed statistically significant results, supporting the once-daily dosing regimen[1].

Perennial Allergic Rhinitis (PAR) Trials

For PAR, key trials include:

  • Studies MP434, MP435, and MP436: These trials assessed the efficacy and safety of azelastine in patients with PAR. Study MP434 demonstrated statistically significant differences for the primary endpoint, supporting the twice-daily dosing regimen. However, MP435 failed to show significant treatment differences for once-daily dosing[1][4].

Safety and Additional Studies

The safety profile of azelastine was evaluated through multiple clinical trials and postmarketing data. Common adverse events reported include dysgeusia, nasal discomfort, epistaxis, headache, sneezing, somnolence, and upper respiratory infection. No new safety issues were identified in the postmarketing databases or medical literature reviews[4].

Market Analysis

Global Market Size and Growth

The global azelastine market is projected to grow significantly over the next few years. As of 2024, the market size is estimated to be USD 1152.2 million, with a compound annual growth rate (CAGR) of 6.20% from 2024 to 2031. This growth is driven by the increasing prevalence of allergic conditions such as rhinitis and conjunctivitis[2][5].

Regional Market Breakdown

  • North America: This region holds the largest market share, with an estimated USD 460.88 million in 2024 and a CAGR of 4.4% from 2024 to 2031. The U.S. is a significant contributor, with a market size of USD 363.63 million in 2024 and a CAGR of 4.2%[2].
  • Europe: Europe accounts for over 30% of the global revenue, with a market size of USD 345.66 million in 2024 and a CAGR of 4.7% from 2024 to 2031[2].
  • Asia-Pacific: This region is expected to experience the highest growth, with a CAGR of 8.2% from 2024 to 2031, driven by increasing urbanization, industrialization, and pollution levels in countries like China and India[2].

Competitive Landscape

The allergic rhinitis treatment market, which includes azelastine, is competitive with major players focusing on strategies such as collaborations and research partnerships. For instance, Stallergenes Greer collaborated with Imperial College London to discover biomarkers for allergen immunotherapy, which could impact the broader market dynamics[3].

Market Projections

Future Growth Drivers

  • Increasing Prevalence of Allergies: The growing prevalence of allergic rhinitis and other allergy disorders is a key driver for the azelastine market. This trend is expected to continue, fueling demand for effective treatment options[2][5].
  • Advances in Medication Delivery: Innovations in nasal sprays and ocular drops have enhanced the efficacy, patient compliance, and convenience of azelastine, contributing to its market growth[5].
  • Expanding Geriatric Population: The growing senior population, which is more susceptible to allergy conditions, is another factor driving market expansion[5].

Geographical Trends

  • Asia-Pacific Growth: The Asia-Pacific region is anticipated to make significant gains due to rapid urbanization, industrialization, and increasing pollution levels, which contribute to higher rates of respiratory allergies[2].

Key Takeaways

  • Clinical Efficacy: Azelastine has demonstrated efficacy in treating both SAR and PAR through multiple clinical trials.
  • Market Growth: The global azelastine market is expected to grow at a CAGR of 6.20% from 2024 to 2031, driven by increasing allergy prevalence and advances in medication delivery.
  • Regional Dominance: North America currently holds the largest market share, but the Asia-Pacific region is expected to experience the highest growth rate.
  • Safety Profile: Azelastine has a well-established safety profile with common adverse events managed effectively.

FAQs

What is the primary use of azelastine?

Azelastine is primarily used to treat allergic rhinitis, including both seasonal (SAR) and perennial (PAR) forms.

What are the common adverse events associated with azelastine?

Common adverse events include dysgeusia, nasal discomfort, epistaxis, headache, sneezing, somnolence, and upper respiratory infection[4].

What is the projected global market size for azelastine by 2031?

The global azelastine market is expected to reach USD 1755.49 million by 2031, growing at a CAGR of 6.20% from 2024 to 2031[2].

Which region is expected to experience the highest growth rate for azelastine?

The Asia-Pacific region is expected to experience the highest growth rate, with a CAGR of 8.2% from 2024 to 2031[2].

What are the key drivers for the growth of the azelastine market?

Key drivers include the increasing prevalence of allergic conditions, advances in medication delivery, and the expanding geriatric population[2][5].

Sources

  1. FDA: 022371 Azelastine Clinical PREA - FDA[1]
  2. Cognitive Market Research: Global Azelastine Market Report 2024[2]
  3. GlobeNewswire: Allergic Rhinitis Treatment Market to Surpass US$ 20,595.6 Million by 2030[3]
  4. FDA: 213872Orig1s000 Integrated Review - Astepro Summary Review for Regulatory Action[4]
  5. Verified Market Research: Azelastine Market Size & Forecast[5]

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.